Tingting Zhang1,
Chen Lu2 
,
Mingming Lv2,
Shengwang Du1,
Xinjun Wu1,
Changqin Wang3
For correspondence:- Chen Lu Email: chen_lu0801@163.com
Accepted: 29 November 2022 Published: 29 December 2022
Citation: Zhang T, Lu C, Lv M, Du S, Wu X, Wang C. Sini San inhibits breast cancer cell migration and angiogenesis via the HIF-1/VEGF pathway. Trop J Pharm Res 2022; 21(12):2575-2581 doi: 10.4314/tjpr.v21i12.11
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the effects of Sini San (SNS) on breast cancer (BC), and the mechanism of action. Methods: MDA-MB-231 and SK-BR-3 cells were used as breast cancer cell models. Cell viability, migration, and invasion were determined by CCK-8, Transwell and wound healing assays, respectively. SNS mechanism of action and its anti-cancer effect were investigated by network pharmacological analysis, and further verified by Immunoblot. Results: Sini San inhibited the proliferation of the breast cancer (BC) cells., and also suppressed the migration as well as the invasion of BC cells, and also restrained the angiogenesis of BC cells. In performing the network pharmacological analysis of Sini Powder in the treatment of BC, 337 drug-disease targets were obtained. PPI network was established through String, and GO and KEGG enrichment analysis was performed on the target sites. KEGG analysis showed that genes were enriched in HIF-1 and VEGF pathways. Conclusion: Sini San suppressed cell migration as well as angiogenesis via the HIF-1 /VEGF pathway.
Archives
News Updates
Fulltext in PDF